![BiopharmIQ by Amp Profile](https://pbs.twimg.com/profile_images/1351686291159658498/ygMd7gQV_x96.jpg)
BiopharmIQ by Amp
@BiopharmIQ
Followers
23K
Following
22K
Statuses
13K
Catalyst Calendar, Big Mover stocks & model portfolios. Database & tools to help with your biotech investing & BD. not invstmnt advice. https://t.co/5njnanqtbK #biotech
Free PDUFA ποΈ β
Joined December 2016
Check out our catalyst calendar π & stay on top of key biopharma readouts π
π $XBI $IBB #biotech
0
0
2
RT @yaireinhorn: An important part of being a content creator on @X should be to promote other valuable accounts as much as possible. So, hβ¦
0
4
0
π Biotech Stock News 02/07 @ Middayπ
π Biotech Stock News 02/07 @ Midday π $TNXP 15% Preliminary Full Year 2024 Report $PTN 10% $4.7M Offering and Placement $SXTP 3% Closing $1.075M Direct Offering $ETON 2% New U.S. Patent for ET-600 $ELDN 2% Tegoprubart Update $LLY 1% Achieve remission on Omvoh for Crohn's $RHHBY 0% Gazyva/Gazyvaro New Data $FENC -1% PEDMARQSI Commercial Launch in Germany $DNLI -1% Tividenofusp Alfa Data Update $GNFT -2% Annual Company UPdate $NVCT -6% Closing of $15.5M Stock Offering $ALMS -12% Alumis & ACELYRIN Merger See the image and comments for more details! πΈπ
0
1
0
RT @learnbiotech: The @X #biotech community is still the most useful for learning, breaking news, and exchanging ideas. Hereβs a list ofβ¦
0
2
0
π Biotech Stock News 02/06 @ Open 𧬠π°
π Biotech Stock News 02/06 @ Open 𧬠π° $RNAZ 35% Completion of Ph1 Cohort 3 Initial Dosing $EQ 17% Itolizumab Ph2 Data $RANI 16% Preclinical Data for Oral Semaglutide Delivery $COYA 10% Inflammatory Blood Markers Improvement with Low-dose IL-2 $SGMO 5% Ph1/2 STAAR Study Data $RLMD 4% Acquires Potential Therapy for Tourette's $MBIO 1% Pricing of $8M Public Offering $REGN 1% Clinical Supply Agreement with Regeneron $DARE 0% Funding Award Notice from NIH for DARE-HPV $BLTE 0% $15M Registered Direct Offering $WVE 0% Initiation Phase 1 INLIGHT Clinical Trial $INSM -1% Brensocatib for Bronchiectasis Priority Review $COEP -1% $10M Series A Financing $MRK -1% Zilovertamab Ph3 waveLINE Trial Initiation $ETON -3% Extension of PDUFA Goal Date for ET-400 $RXRX -4% REC-994 Ph2 Data Presentation $VKTX -5% Ph3 for VK2735 in Q2 2025 $XFOR -6% Announces Strategic Restructuring $LPCN -8% Updated Regulatory Guidance on LPCN 1154 $KURA -9% Ziftomenib Data & FDA Feedback $TNXP -13% Ph1 Topline Results for TNX-1500 $VIRX -60% Ceases Operations See image for details. πΈ π π Also check out @Biotech2k1 thoughts on the latest $VKTX update. Are investors just way too impatient these days? π€
0
1
1